BLB&B Advisors LLC decreased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.8% in the third quarter, Holdings Channel reports. The firm owned 147,650 shares of the company’s stock after selling 2,650 shares during the quarter. BLB&B Advisors LLC’s holdings in Ionis Pharmaceuticals were worth $6,697,000 as of its most recent SEC […]
StockNews.com cut shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) from a hold rating to a sell rating in a research report report published on Tuesday. IONS has been the topic of a number of other reports. Morgan Stanley lifted their price objective on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the […]
StockNews.com downgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) from a hold rating to a sell rating in a report released on Tuesday morning. A number of other research firms have also issued reports on IONS. Raymond James started coverage on Ionis Pharmaceuticals in a report on Thursday, September 28th. They issued a strong-buy […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a research report issued on Monday, RTT News reports. Several other brokerages also recently issued reports on IONS. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its target price raised by equities research analysts at The Goldman Sachs Group from $25.00 to $28.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “sell” rating on the stock. The Goldman Sachs Group’s price objective points to a potential downside […]